Company / Capital Expenditures
TENAX THERAPEUTICS, INC. Capital Expenditures History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.8K
FY2016
5-year range
$9.8K / $17.2K
FY2012-FY2016
Trend
+0.0%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $17,199 to $9,804 over the past 2 years.
Based on SEC 10-K filings.
$9,804 in FY2016 with a 3-year CAGR of -17.8%.
Declined from $17,199 to $9,804 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -17.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -17.8%, indicating a declining trend.
- In FY2016, capital expenditures increased 0.0% year-over-year.
- Peak capital expenditures was recorded in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2016 | $9.8K | +0.0% |
| FY2015 | $9.8K | -43.0% |
| FY2014 | $17.2K | -2.6% |
| FY2013 | $17.7K | -92.7% |
| FY2012 | $240.8K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026